Emerging Markets On Executives’ Minds At JPM15
This article was originally published in PharmAsia News
Several top executives from major multinationals made comments on emerging market strategies at the JP Morgan Healthcare Conference in San Francisco Jan. 12-15 that piqued the interest of PharmAsia News. Among them, GSK said it was looking for a broad product portfolio, Lilly noted it had doubled its sales in China and Becton Dickinson highlighted the need to develop targeted products.
You may also be interested in...
GlaxoSmithKline has joined a growing list of big pharma companies expanding in China, launching a research and development center based in Shanghai, the company announced May 24
As China tightens its grip over clinical research using human genetic data in the country, and the US increases scrutiny over the use of personal data, multinational drug developers may face a difficult choice or even create separate entities to cater to local regulatory requirements. WuXi NextCODE provides one interesting case study.
Amid a sweeping National Security Law passage, many biotech and healthcare firms from China opt for a Hong Kong initial public offering in the meanwhile appetite for a US listing wanes.